ATAI | LIFE SCIENCES
310
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-310,,qode-page-loading-effect-enabled,qode-title-hidden,qode_grid_1300,qode-child-theme-ver-1.0.0,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.6,vc_responsive

Enabling longer,
healthier and happier lives.
For everyone.

Our Vision

Ultimately cure
aging and mental health disorders

ATAI Life Sciences AG is a Berlin and New York based, internationally active biotech company builder with the vision to cure aging and mental health disorders.

To deliver on this vision we follow a decentralized and data-driven platform approach that leverages artificial intelligence (AI), access to talent and financial resources to develop paradigm-shifting compounds.

We re-think every step in drug development and strongly believe in the power of technology to systematically reduce time and cost in the development of mental health and longevity therapies.

In line with our platform strategy, we launch and acquire companies to develop new pharmaceutical drugs but also look into other areas such as digital therapeutics.

Focus
Mental health

ATAI is particularly exploring formerly “vilified” compounds – such as psilocybin and ketamine – to create new paths to treat and cure multiple forms of mental health conditions

Focus
Longevity

ATAI is looking into different ways to increase the human lifespan and reverse aging

Focus
AI & Big Data

ATAI is leveraging the potential of AI and big data analytics to optimize and accelerate the process of pre-clinical & clinical drug development

Our Strategy

The evolution of biotech
Science fiction becomes reality

Technology has kicked off a new era of biotech, outpacing Moore’s law. We acquire compounds that can benefit from leveraging this technological advancement by developing them on our platform. Compounds that we acquire are in general at an early stage of the drug development process.

We envision to put an end to aging and mental health disorders. To deliver on this vision, we initially focus on developing solutions for people that suffer from a real unmet medical need – starting with the 320mn patients that suffer from depression.

We believe that small teams are more effective and efficient. Our decentralized and lean setup allows us to constantly spread learning, expertise and best practices across the ATAI platform enabling operational excellence and entrepreneurship.

World-class business and science experts ensure successful execution of acquisitions and pre-clinical & clinical studies in record speed.

Our Team

Vast experience
and great access to deal flow

Christian Angermayer

Founder

Lars Wilde

Co-Founder

Florian Brand

Co-Founder & CEO

Simon Seibold

Associate

Philipp Schreiber

Associate

Our Platform Companies

A portfolio of innovation
Accelerating progress in life sciences

COMPASS

COMPASS is developing psilocybin therapy for patients with treatment-resitant depression.
www.compasspathways.com

Perception Neuroscience

Perception Neuroscience is developing arketamine therapy for patients with neuropsychiatric diseases.
perceptionneuroscience.com

Innoplexus

Innoplexus leverages the power of AI and big data analytics for a variety of applications in life sciences, like drug development.
www.innoplexus.com

Juvenescence

Juvenescence invests in companies with therapies for ageing and age-related diseases.
www.juvenescence.ltd

Insights

Learn about cutting-edge science
and gain life-enhancing insights

Follow us on Twitter and read our blog

Careers

Work with us
on improving the lives of millions of people

WE ARE HIRING! Learn about career opportunities at ATAI and see open jobs across our platform companies.

Let’s stay in touch

Don’t miss any new developments by signing up to our newsletter:

75%

A biography (or simply bio) is a detailed description of a person’s life. It involves more than just the basic facts like education, work, relationships.

43%

A biography (or simply bio) is a detailed description of a person’s life. It involves more than just the basic facts like education, work, relationships.

87%

A biography (or simply bio) is a detailed description of a person’s life. It involves more than just the basic facts like education, work, relationships.

ATAI is looking into different ways to increase the human lifespan and reverse aging

Based on recent technological advances in areas like genomics, stem cell therapy, immunology and nanotechnology, humankind will be able not only live longer but also healthier.

We believe that (a) the future of medicine will be personalized, (b) we have to follow a pro-active and preventive approach to avoid diseases or at least detect them earlier, (c) we have to eliminate cellular senescence, (d) we have to improve the process of autophagy to help to cure neurodegenerative diseases and (e) we have to leverage the potential of neurotechnology and cognitive enhancement.

Christian Angermayer

Founder

Strategy & Investor Relations

Lars Wilde

Co-Founder

Drug discovery & Compound sourcing

Florian Brand

Co-Founder & CEO

Drug development & Operations

Simon Seibold

Associate

Investments & Business Development

Philipp Schreiber

Associate

Drug discovery & Compound sourcing

ATAI is particularly exploring formerly “vilified” compounds – such as psychedelics – to create new paths to cure multiple forms of mental health conditions

Depression, anxiety, post-traumatic stress disorder, obsessive-compulsive disorder, bipolar disorder and other psychiatric conditions are increasingly becoming a burden for humankind.

We believe that (a) existing and new compounds such as psychedelics provide the opportunity to significantly advance psychiatry, (b) treatment solutions should be as convenient, cost-efficient and fast as possible, (c) clinical evidence has to meet the highest scientific standards, (d) fully integrated mental health solutions are the future.

ATAI is leveraging the potential of AI and big data analytics to optimize and accelerate the process of pre-clinical & clinical drug development

Technological innovations allow us consolidate and utilize vast amounts of previously inaccessible data.

We believe that (a) proven technology can be used to accelerate the identification and incubation of high-impact compounds, (b) AI and big data facilitate clinical trial design, comparison and decision support, (d) AI has a leading role in developing personalized therapeutics, (e) predictive analytics through unified machine learning models help us to predict the toxicity of drugs and efficacy of combination therapeutics.

Sorry,

there are no positions available at this time.

Please check back soon.